Shares of Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.03 and traded as low as $0.00. Nascent Biotech shares last traded at $0.00, with a volume of 100 shares.
Nascent Biotech Price Performance
About Nascent Biotech
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
Further Reading
- Five stocks we like better than Nascent Biotech
- What is the S&P/TSX Index?
- Nextracker’s Solar Surge: Will It Shatter Its All-Time High?
- Investing in Travel Stocks Benefits
- Savvy Investors Are Raising a Glass for Heineken Stock
- Why Are These Companies Considered Blue Chips?
- Top 4 ETFs for China Exposure After Tariff Relief
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
